After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NYSE listed company, DNA falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Ginkgo Bioworks Holdings Inc is $1.94B. A total of 48.45 million shares were traded on the day, compared to an average of 30.59M shares.
In the most recent transaction, Coen Steven P. sold 131,928 shares of DNA for 0.84 per share on May 02 ’24. After the transaction, the insider now owns 162,527 company shares. In a previous transaction on May 02 ’24, Dmytruk Mark E. sold 47,806 shares at 0.84 per share. DNA shares that the insider owns now total 925,400.
Among the insiders who sold shares, Dmytruk Mark E. disposed of 51,169 shares on Apr 02 ’24 at a per-share price of $1.05. This resulted in the insider holding 865,079 shares of DNA after the transaction. In another insider transaction, Dmytruk Mark E. sold 38,826 shares at $1.26 per share on Mar 04 ’24. Company shares held by the insider now total 808,125.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, DNA has a high of $2.55 and a low of $0.74.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. DNA’s latest balance sheet shows that the firm has $1.55B in Cash & Short Term Investments as of fiscal 2021. There were $23.03M in debt and $134.76M in liabilities at the time. Its Book Value Per Share was $0.58, while its Total Shareholder’s Equity was $1.57B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DNA is Buy with a score of 2.86.
